Circulation

Population Screening With Natriuretic Peptides Is Ready for Prime Time

TET2-Mutant Clonal Hematopoiesis Promotes Heart Failure With Preserved Ejection Fraction

Response by Maurizi et al to Letter Regarding Article, “Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry”

Cardiac Biomarkers in Patients With Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial

BACKGROUND: The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic va...

Letter by Zhang and Zeng Regarding Article, “Long-Term Outcomes After Septal Reduction Therapies in Obstructive Hypertrophic Cardiomyopathy: Insights From the SHARE Registry”

A Novel Hidden Protein p-414aa Encoded by <i>circSETD2(14,15</i> ) Inhibits Vascular Remodeling

BACKGROUND: Phenotypic switching of vascular smooth muscle cells (VSMCs), leading to neointimal hyperplasia, is a fundamental cause of vascular remodeling diseases such as atherosclerosis...

Hierarchical Composite Outcomes and Win Ratio Methods in Cardiovascular Trials: A Review and Consequent Guidance

The win ratio is a method for analyzing a hierarchical composite outcome. It has been most widely used in randomized clinical trials (RCTs) in cardiovascular disease. We performed a review of cardiova...

Biomarkers to Guide the Timing of Aortic Valve Replacement in Asymptomatic Aortic Stenosis: Where Do We Stand After Early TAVR?

XBP1s-EDEM2 Prevents the Onset and Development of HFpEF by Ameliorating Cardiac Lipotoxicity

BACKGROUND: Morbidity and mortality of heart failure with preserved ejection fraction (HFpEF) is increased in metabolic disorders. However, options for preventing and treating these preval...